Developing Context Appropriate Toxicity Testing Approaches Using New Alternative Methods (NAMs)

被引:40
作者
Andersen, Melvin E. [1 ]
McMullen, Patrick D. [1 ]
Phillips, Martin B. [1 ]
Yoon, Miyoung [2 ,3 ]
Pendse, Salil N. [1 ]
Clewell, Harvey J. [2 ,4 ]
Hartman, Jessica K. [1 ]
Moreau, Marjory [1 ]
Becker, Richard A. [5 ]
Clewell, Rebecca A. [2 ,6 ]
机构
[1] ScitoVat LLC, 100 Capitola Dr Suite 106, Durham, NC 27713 USA
[2] ScitoVat LLC, Res Triangle Pk, NC USA
[3] ToxStrategies, Cary, NC USA
[4] Ramboll, Res Triangle Pk, NC USA
[5] Amer Chem Council, Washington, DC USA
[6] 21st Century Tox Consulting, Chapel Hill, NC USA
关键词
IN-VIVO EXTRAPOLATION; VITRO; RISK; SAFETY; CHEMICALS; PATHWAYS; TOXICOLOGY; MODELS; PRIORITIZATION; METABOLISM;
D O I
10.14573/altex.1906261
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In the past 10 years, the public, private, and non-profit sectors have found agreement that hazard identification and risk assessment should capitalize on the explosion of knowledge in the biological sciences, moving away from in life animal testing toward more human-relevant in vitro and in silico methods, collectively referred to as new approach methodologies (NAMs). The goals for implementation of NAMs are to efficiently identify possible chemical hazards and to gather dose-response data to inform more human-relevant safety assessment. While work proceeds to develop NAMs, there has been less emphasis on creating decision criteria or showing how risk context should guide selection and use of NAMs. Here, we outline application scenarios for NAMs in different risk contexts and place different NAMs and conventional testing approaches into four broad levels. Level 1 relies solely on computational screening; Level 2 consists of high throughput in vitro screening with human cells intended to provide broad coverage of possible responses; Level 3 focuses on fit-for-purpose assays selected based on presumptive modes of action (MOA) and designed to provide more quantitative estimates of relevant dose responses; Level 4 has a variety of more complex multi-dimensional or multi-cellular assays and might include targeted in vivo studies to further define MOA. Each level also includes decision-appropriate exposure assessment tools. Our aims here are to (1) foster discussion about context-dependent applications of NAMs in relation to risk assessment needs and (2) describe a functional roadmap to identify where NAMs are expected to be adequate for chemical safety decision-making.
引用
收藏
页码:523 / 534
页数:12
相关论文
共 80 条
  • [1] Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment
    Adeleye, Yeyejide
    Andersen, Melvin
    Clewell, Rebecca
    Davies, Michael
    Dent, Matthew
    Edwards, Sue
    Fowler, Paul
    Malcomber, Sophie
    Nicol, Beate
    Scott, Andrew
    Scott, Sharon
    Sun, Bin
    Westmoreland, Carl
    White, Andrew
    Zhang, Qiang
    Carmichael, Paul L.
    [J]. TOXICOLOGY, 2015, 332 : 102 - 111
  • [2] Andersen Melvin E., 2018, Current Opinion in Toxicology, V9, P21, DOI 10.1016/j.cotox.2018.05.003
  • [3] The Vision of Toxicity Testing in the 21st Century: Moving from Discussion to Action
    Andersen, Melvin E.
    Krewski, Daniel
    [J]. TOXICOLOGICAL SCIENCES, 2010, 117 (01) : 17 - 24
  • [4] [Anonymous], EST PROGR INT SUIT M
  • [5] Recommendation on Test Readiness Criteria for New Approach Methods in Toxicology: Exemplified for Developmental Neurotoxicity
    Bal-Price, Anna
    Hogberg, Helena T.
    Crofton, Kevin M.
    Daneshian, Mardas
    FitzGerald, Rex E.
    Fritsche, Ellen
    Heinonen, Tuula
    Bennekou, Susanne Hougaard
    Klima, Stefanie
    Piersma, Aldert H.
    Sachana, Magdalini
    Shafer, Timothy J.
    Terron, Andrea
    Monnet-Tschudi, Florianne
    Viviani, Barbara
    Waldmann, Tanja
    Westerink, Remco H. S.
    Wilks, Martin F.
    Witters, Hilda
    Zurich, Marie-Gabrielle
    Leist, Marcel
    [J]. ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2018, 35 (03) : 306 - 352
  • [6] Barakat R R, 1995, Oncology (Williston Park), V9, P129
  • [7] Barakat R.R., 1995, ONCOLOGY, V9, P142
  • [8] Barakat R.R., 1995, ONCOLOGY, V9, P139
  • [9] Beames T., TOXICOL APPL PHARM
  • [10] An exposure:activity profiling method for interpreting high-throughput screening data for estrogenic activity-Proof of concept
    Becker, Richard A.
    Friedman, Katie Paul
    Simon, Ted W.
    Marty, M. Sue
    Patlewicz, Grace
    Rowlands, J. Craig
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2015, 71 (03) : 398 - 408